<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-14T19:08:52Z</responseDate><request verb="GetRecord" identifier="oai:uvadoc.uva.es:10324/55178" metadataPrefix="rdf">https://uvadoc.uva.es/oai/request</request><GetRecord><record><header><identifier>oai:uvadoc.uva.es:10324/55178</identifier><datestamp>2022-09-19T19:00:17Z</datestamp><setSpec>com_10324_1134</setSpec><setSpec>com_10324_931</setSpec><setSpec>com_10324_894</setSpec><setSpec>col_10324_1213</setSpec></header><metadata><rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
<ow:Publication rdf:about="oai:uvadoc.uva.es:10324/55178">
<dc:title>Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population</dc:title>
<dc:creator>Blanco Durango, Belén</dc:creator>
<dc:creator>Perez Simon, José Antonio</dc:creator>
<dc:creator>Sánchez Abarca, Luis Ignacio</dc:creator>
<dc:creator>Caballero Velazquez, Teresa</dc:creator>
<dc:creator>Gutierrez Cossio, Silvia</dc:creator>
<dc:creator>Hernández Campo, Pilar</dc:creator>
<dc:creator>Diez Campelo, María</dc:creator>
<dc:creator>Herrero Sánchez, María del Carmen</dc:creator>
<dc:creator>Rodríguez Serrano, Concepción</dc:creator>
<dc:creator>Santamaría Quesada, Carlos</dc:creator>
<dc:creator>Sánchez Guijo, Fermín</dc:creator>
<dc:creator>Cañizo Fernández-Roldán, Consuelo del</dc:creator>
<dc:creator>San Miguel Izquierdo, Jesús F.</dc:creator>
<dc:subject>Cell Biology</dc:subject>
<dc:subject>Graft versus host disease</dc:subject>
<dc:subject>Cell transplantation</dc:subject>
<dc:subject>Trasplante de células</dc:subject>
<dc:subject>Medical microbiology</dc:subject>
<dc:subject>Pharmacology</dc:subject>
<dc:description>Producción Científica</dc:description>
<dc:description>Background In vitro depletion of alloreactive T cells using the proteasome inhibitor bortezomib is a promising approach to prevent graft-versus-host disease after allogeneic stem cell transplantation. We have previously described the ability of bortezomib to selectively eliminate alloreactive T cells in a mixed leukocyte culture, preserving non-activated T cells. Due to the role of regulatory T cells in the control of graft versus host disease, in the current manuscript we have analyzed the effect of bortezomib in regulatory T cells.Design and Methods Conventional or regulatory CD4+ T cells were isolated with immunomagnetic microbeads based on the expression of CD4 and CD25. The effect of bortezomib on T-cell viability was analyzed by flow cytometry using 7-amino-actinomycin D staining. To investigate the possibility of obtaining an enriched regulatory T-cell population in vitro with the use of bortezomib, CD4+ T cells were cultured during four weeks in the presence of anti-CD3 and anti-CD28 antibodies, IL-2 and bortezomib. The phenotype of these long-term cultured cells was studied, analyzing the expression of CD25, CD127 and FOXP3 by flow cytometry, and mRNA levels were determined by RT-PCR. Their suppressive capacity was assessed in co-culture experiments, analyzing proliferation and IFN-γ and CD40L expression of stimulated responder T cells by flow cytometry.Results We observed that naturally occurring CD4+CD25+ regulatory T cells are resistant to the pro-apoptotic effect of bortezomib. Furthermore, we found that long-term culture of CD4+ T cells in the presence of bortezomib promotes the emergence of a regulatory T-cell population that significantly inhibits proliferation, IFN-γ production and CD40L expression among stimulated effector T cells.Conclusions These results reinforce the proposal of using bortezomib in the prevention of graft versus host disease and, moreover, in the generation of regulatory T-cell populations, that could be used in the treatment of multiple T-cell mediated diseases.</dc:description>
<dc:date>2022-09-19T08:26:32Z</dc:date>
<dc:date>2022-09-19T08:26:32Z</dc:date>
<dc:date>2009</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:identifier>Haematologica, 2009, Vol. 94, Nº. 7, págs. 975-983</dc:identifier>
<dc:identifier>0390-6078</dc:identifier>
<dc:identifier>https://uvadoc.uva.es/handle/10324/55178</dc:identifier>
<dc:identifier>10.3324/haematol.2008.005017</dc:identifier>
<dc:identifier>975</dc:identifier>
<dc:identifier>7</dc:identifier>
<dc:identifier>983</dc:identifier>
<dc:identifier>Haematologica</dc:identifier>
<dc:identifier>94</dc:identifier>
<dc:identifier>1592-8721</dc:identifier>
<dc:language>eng</dc:language>
<dc:relation>https://haematologica.org/article/view/5306</dc:relation>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:rights>http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
<dc:rights>© Ferrata Storti Foundation</dc:rights>
<dc:rights>Attribution-NonCommercial-NoDerivatives 4.0 Internacional</dc:rights>
<dc:publisher>Ferrata Storti Foundation</dc:publisher>
<dc:peerreviewed>SI</dc:peerreviewed>
</ow:Publication>
</rdf:RDF></metadata></record></GetRecord></OAI-PMH>